Enhancement by oxiracetam of passive avoidance improvement induced by the presynaptic muscarinic antagonist secoverine in mice.
Istituto di Psicobiologia e Psicofarmacologia, CNR, Rome, Italy.
- Published Article
Behavioural Brain Research
- Publication Date
Mar 15, 1992
Post-trial administration of secoverine (0.5, 1 and 2.5 mg/kg), a presynaptic muscarinic blocker, improved retention in mice tested in a passive avoidance task. The nootropic drug oxiracetam (50 mg/kg), given before both acquisition and retention trial, had no effect alone, but significantly enhanced secoverine improving effects. Performance improvements were also found in combining ineffective doses of the two compounds. Even if not necessarily through a direct and specific action, oxiracetam might activate cholinergic function. Thus, performance improvements resulting from the combination of oxiracetam and secoverine may be due to a simultaneous activation of different cholinergic mechanisms.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 04/19/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/1571105